Expertise in
10
conditions

Dr. Anna Farago

Oncology
Mass General Waltham Pharmacy
52 Second Ave, 
Waltham, MA 
Expertise in
10
conditions
Mass General Waltham Pharmacy
52 Second Ave, 
Waltham, MA 

Overview

Anna Farago is an Oncologist practicing medicine in Waltham, Massachusetts.

Dr. Farago is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and EGFR Positive Lung Cancer.

She is actively involved in clinical research, co-authoring 55 peer reviewed articles and participating in 7 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in MA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Mass General Waltham Pharmacy
52 Second Ave, Waltham, MA 02451

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients With Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors
Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients With Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors
Enrollment Status: Terminated
Publish Date: October 17, 2023
Intervention Type: Biological, Drug
Study Drugs: Navitoclax, Vistusertib
Study Phase: Phase 1/Phase 2
Phase I/II Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Phase I/II Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Enrollment Status: Unknown
Publish Date: February 07, 2022
Intervention Type: Drug
Study Drugs: Olaparib, Temozolomide
Study Phase: Phase 1/Phase 2
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Enrollment Status: Completed
Publish Date: October 28, 2021
Intervention Type: Drug
Study Phase: Phase 3
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

55 Total Publications

Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data.
Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data.
Journal: Cancer research communications
Published: December 05, 2024
Similar Doctors
Expertise in
33
conditions
Dr. Edwin Choy
Oncology
Expertise in
33
conditions
Dr. Edwin Choy
Oncology

Office

52 Second Ave Ste 1110, 
Waltham, MA 
 (9.9 miles away)
781-487-6100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Edwin Choy is an Oncologist practicing medicine in Waltham, Massachusetts. Dr. Choy is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Osteosarcoma, and Synovial Sarcoma.

Expertise in
12
conditions
Dr. Lecia Van Dam Sequist
Oncology
Expertise in
12
conditions
Dr. Lecia Van Dam Sequist
Oncology

The General Hospital Corporation

40 2nd Ave, 
Waltham, MA 
 (10.3 miles away)
781-487-2900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lecia Van Dam Sequist is an Oncologist practicing medicine in Waltham, Massachusetts. Dr. Van Dam Sequist is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Tissue Biopsy. Dr. Van Dam Sequist is board certified in Medical Oncology.

Expertise in
28
conditions
Dr. Jeremy Abramson
Oncology
Expertise in
28
conditions
Dr. Jeremy Abramson
Oncology

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeremy Abramson is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Abramson is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Anna Farago

How do I make an appointment with Dr. Anna Farago?

You can book an appointment with Dr. Anna Farago by calling their office at 781-487-6100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anna Farago a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anna Farago is classified as an Elite expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anna Farago specialize in?

While Dr. Anna Farago is a Oncology, they have specific expertise in Small Cell Lung Cancer (SCLC), Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Anna Farago participate in research or clinical trials?

Yes. Dr. Anna Farago has published 55 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. Anna Farago's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Farago's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 7 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile